Results 141 to 150 of about 109,722 (264)

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

open access: yesBritish Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß   +3 more
wiley   +1 more source

Proof-of-concept study for the detection of somatic structural variant driver alterations using HiFi long-read sequencing in a pediatric leukemia cohort. [PDF]

open access: yesNPJ Genom Med
Lansdon LA   +25 more
europepmc   +1 more source

Blocking SETD2 Enhances the Therapeutic Efficiency of Menin Inhibitor in MLL‐Fusion Leukemia

open access: yesCancer Science, EarlyView.
Combined SETD2 and menin inhibitors make synergistic effects against MLL‐fusion leukemia; the combination therapy reduces the expression of target genes through blocking transcription elongation and initiation. ABSTRACT During transcriptional elongation, the histone methyltransferase SETD2 binds to RNA polymerase II and deposits trimethylation marks at
Anpei Li   +10 more
wiley   +1 more source

Impact of oral mucositis treated by photobiomodulation protocol on the quality of life of pediatric oncology patients with acute lymphoblastic leukemia. [PDF]

open access: yesLasers Med Sci
Alves de Melo Júnior W   +5 more
europepmc   +1 more source

MTAP Deficiency as a Metabolic Vulnerability in Cancer: Implications for Synthetic Lethal Therapy

open access: yesCancer Science, EarlyView.
MTAP deletion creates a therapeutically actionable metabolic vulnerability through MTA accumulation and PRMT5 dependency. This review summarizes the biochemical basis of MTAP‐directed synthetic lethality, emerging PRMT5/MAT2A inhibitors, clinicogenomic features of MTAP‐deleted tumors, and future strategies for precision oncology.
Hiroaki Ikushima, Hidenori Kage
wiley   +1 more source

BCL‐2 and MCL1 co‐inhibition enhances glucocorticoid therapy in preclinical models of infant KMT2A‐rearranged acute lymphoblastic leukaemia

open access: yes
British Journal of Haematology, EarlyView.
Mawar Karsa   +19 more
wiley   +1 more source

Optimising Haematopoietic Stem Cell Transplantation: Enhancing Myeloablation Sensitivity and Alleviating Anaemia Using Roxadustat (FG‐4592)

open access: yesCell Proliferation, EarlyView.
The use of FG‐4592 in the process of myeloablation can promote haematopoietic cell apoptosis for more effective myeloablation, maintain the number of RBC and may create a pluripotent microenvironment suitable for donor cells, so as to enable more effective haematopoietic reconstruction of donor cells in vivo.
Guanheng Yang   +8 more
wiley   +1 more source

Macular Hemorrhage as the First Manifestation of Leukemia. [PDF]

open access: yesDiagnostics (Basel)
Wójcik-Niklewska B   +2 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy